Hyper-CVAD/MA化疗方案临床应用的研究进展  

Research Progress of Clinical Application of Hyper-CVAD /MA Chemotherapy

作　　者：李四强[1] 侯忠赤[1] 宫超[1] 

机构地区：[1]中国人民解放军第二五二中心医院血液科,河北保定071000

出　　处：《医学综述》2014年第3期460-463,共4页Medical Recapitulate

摘　　要：Hyper-CVAD/MA化疗方案根据伯基特淋巴瘤/急性淋巴细胞白血病细胞增殖周期与环磷酰胺的半衰期关系设计,其优点是尽可能覆盖肿瘤细胞增殖周期,同时在杀灭肿瘤细胞的同时用强化疗方案又可以避免耐药发生,是目前治疗淋巴系统恶性肿瘤的主要方案之一,尤其对于难治/复发患者更是如此。近年来,该方案联合分子靶向药物、干细胞移植等治疗特殊类型非霍奇金淋巴瘤/急性淋巴细胞白血病成为新的趋势。Hyper-CVAD/MA chemotherapy is designed accorchng to the relation between cell prolieration cycle of Bunkitt＇s lymphoma/acute lymphoblastic leukemia and the half-life of eyclophosphamide. The advantages of the chemotherapy is that it not only covers proliferation cycle of tumor cells as much as possible,but also prevents drug resistance,which is one of the major chemotherapies for Lymphatic system malignant tumors at present, particularly for relapsed or refractory patients. In recent years, the chemotherapy combined with molecular targeted drugs and stem cell transplantation for special types of NHL/ALL has become a new tread.

关 键 词：HYPER-CVAD MA 化疗 淋巴瘤 白血病 

分 类 号：R733.4[医药卫生—肿瘤]